The Lupus Foundation of America has scheduled its 10th Walk to End Lupus Now in New York City for Saturday, May 6, to recognize those living with lupus, honor those lost by the disease and fulfill the organization’s vision of a life free of lupus. Since 2008, participants have raised more than…
Benlysta reduced systemic lupus erythematosus (SLE) activity and improved patient outcomes, but smokers and those with significant organ damage failed to respond as well to it, according to a Swedish study. The findings could help doctors determine which patients could benefit the most from Benlysta, also known as belimumab or LymphoStat-B. The…
Sun exposure and ultraviolet lights can trigger many unpleasant symptoms for lupus patients like skin rashes, joint pain, fatigue and swelling of internal organs. With help from healthline.com, we’ve put together some tips and tricks to keep you safe from the sun this summer: Sun Screen Try to limit the time you…
Canada’s Aurinia Pharmaceuticals is one step closer to releasing voclosporin — a new drug now being developed to treat active lupus nephritis (LN). In a press release, Aurinia announced plans for a Phase 3 clinical trial (AURORA; NCT03021499). Along with ongoing discussions with both the European Medicines Agency (EMA) and Japan’s…
Infants with neonatal lupus syndrome can have autoantibodies that fight other autoantibodies. In this case, the autoantibodies doing the targeting are fighting SSA/Ro autoantibodies associated with the development of autoimmune diseases. Now researchers have discovered that most infants with neonatal lupus syndrome who have the autoantibodies that fight SSA/Ro develop mild…
Nearly 300 leaders in the New York fashion, entertainment and entertainment world gathered at the Plaza Hotel on April 4 for the 8th Annual Lupus Handbag Luncheon & Silent Auction. The event — the first hosted by the newly formed Lupus Research Alliance — raised an unspecified amount of money for lupus…
A therapy that XTL Biopharmaceuticals is developing for autoimmune diseases significantly reduced the expression of several cell signaling molecules called cytokines that play a role in the development of Sjögren’s syndrome (SS) associated with lupus, the company reported. The news came in a press release updating XTL’s efforts to develop hCDR1 for systemic…
New research from Switzerland reported that disease activity in patients with systemic lupus erythematosus (SLE) has a negative impact on the quality of life of these patients. The study, titled “Impact of disease activity on health-related quality of life in systemic lupus erythematosus — a cross-sectional analysis of the Swiss Systemic…
Results from the Phase 2 BUTTERFLY trial conducted by Pfizer suggest that an antibody against the pro-inflammatory cytokine interleukin-6 (IL-6) may be a promising treatment for systemic lupus erythematosus (SLE). The study, “Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II…
The Lupus Research Alliance has chosen its Novel Research Grant Class of 2017, which consists of 10 projects that represent innovative approaches in lupus-treatment development. “Standing on a 16-year foundation of documented success, the Novel Research Grants bring new insight and untried directions to the complexities of lupus,” Margaret Dowd, the…